Canada Markets closed

Inovio Pharmaceuticals, Inc. (INO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.9900+0.1000 (+5.29%)
At close: 04:00PM EDT
1.9800 -0.01 (-0.50%)
After hours: 05:52PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.8900
Open1.9200
Bid1.9600 x 40000
Ask1.9900 x 34100
Day's Range1.8800 - 2.0100
52 Week Range1.6000 - 10.3300
Volume6,036,976
Avg. Volume5,024,843
Market Cap418.668M
Beta (5Y Monthly)0.65
PE Ratio (TTM)N/A
EPS (TTM)-1.1100
Earnings DateFeb 28, 2022 - Mar 04, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.67
  • Motley Fool

    Is This Vaccine Stock in Trouble -- or Ready for a Rebound?

    In the early days of the coronavirus vaccine race, Inovio Pharmaceuticals (NASDAQ: INO) was one of the favorites. One major headwind slowed things down: The U.S. Food and Drug Administration (FDA) placed Inovio's coronavirus vaccine trial on a partial clinical hold in late 2020. Does all of this mean Inovio is in trouble?

  • Zacks

    Inovio Pharmaceuticals (INO) Reports Q1 Loss, Lags Revenue Estimates

    Inovio (INO) delivered earnings and revenue surprises of -28.57% and 56.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • Reuters

    UPDATE 2-Inovio to discontinue COVID vaccine trial, appoints Jacqueline Shea as CEO

    Inovio Pharmaceuticals Inc will discontinue a late-stage study of its COVID-19 vaccine, the company said on Tuesday, and appointed its operating chief as the new chief executive, sending the company's shares down nearly 20% after the bell. The decision on the trial comes after emerging global data showed a lower incidence of severe COVID cases, which would lead to an increase in trial size and costs, the company said. The biotechnology company's new strategy also comes with a change at the helm, with Jacqueline Shea taking over as CEO, effective immediately.